Jazz Pharmaceuticals Plc (JAZZ)
246.81
-0.76
(-0.30%)
USD |
NASDAQ |
Sep 04, 16:00
246.82
+0.01
(+0.00%)
After-Hours: 20:00
Jazz Pharmaceuticals SG&A Expense (TTM) : 1.679B for June 30, 2026
SG&A Expense (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical SG&A Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 1.679B |
| March 31, 2026 | 1.648B |
| December 31, 2025 | 1.809B |
| September 30, 2025 | 1.772B |
| June 30, 2025 | 1.567B |
| March 31, 2025 | 1.548B |
| December 31, 2024 | 1.385B |
| September 30, 2024 | 1.412B |
| June 30, 2024 | 1.395B |
| March 31, 2024 | 1.397B |
| December 31, 2023 | 1.343B |
| September 30, 2023 | 1.330B |
| June 30, 2023 | 1.380B |
| March 31, 2023 | 1.406B |
| December 31, 2022 | 1.417B |
| September 30, 2022 | 1.432B |
| June 30, 2022 | 1.437B |
| March 31, 2022 | 1.500B |
| December 31, 2021 | 1.452B |
| September 30, 2021 | 1.300B |
| June 30, 2021 | 1.144B |
| March 31, 2021 | 906.34M |
| December 31, 2020 | 854.23M |
| September 30, 2020 | 821.34M |
| June 30, 2020 | 792.79M |
| Date | Value |
|---|---|
| March 31, 2020 | 777.40M |
| December 31, 2019 | 736.94M |
| September 30, 2019 | 684.53M |
| June 30, 2019 | 661.70M |
| March 31, 2019 | 644.26M |
| December 31, 2018 | 683.53M |
| September 30, 2018 | 664.72M |
| June 30, 2018 | 633.36M |
| March 31, 2018 | 607.11M |
| December 31, 2017 | 544.16M |
| September 30, 2017 | 528.25M |
| June 30, 2017 | 528.09M |
| March 31, 2017 | 518.38M |
| December 31, 2016 | 502.89M |
| September 30, 2016 | 501.31M |
| June 30, 2016 | 480.98M |
| March 31, 2016 | 465.50M |
| December 31, 2015 | 449.12M |
| September 30, 2015 | 429.26M |
| June 30, 2015 | 418.72M |
| March 31, 2015 | 412.14M |
| December 31, 2014 | 406.11M |
| September 30, 2014 | 381.72M |
| June 30, 2014 | 363.19M |
| March 31, 2014 | 340.14M |
SG&A Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
SG&A Expense (TTM) Benchmarks
| Avadel Pharmaceuticals Plc | 191.46M |
| Perrigo Co. Plc | 997.20M |
| GH Research Plc | 24.75M |
| Cosmo NV | 34.02M |
| Axsome Therapeutics, Inc. | 712.66M |